Guanidine salts—more compatible! Leading Medical’s new patent tackles the “bottleneck” challenge in viral preservation solutions.
Recently, Leading Medical has been granted another invention patent! A non-guanidinium salt–based viral preservation solution compatible with nucleic acid extraction, along with its preparation method and applications. By establishing a novel non-guanidine‑salt technology platform, we have addressed the key pain points of conventional guanidine‑salt formulations, delivering a more stable and highly compatible sample‑preservation solution.
Technological Breakthrough: Comprehensive Optimization of the Novel Non-Guanidinium Salt System
Leading Medical uses P(HEMA‑BAMPD hydrochloride) as its core ingredient, combined with buffers, chelating agents, and carbohydrate stabilizers. Through electrostatic adsorption and hydrogen bonding, it protects viral nucleic acids, inhibits nuclease activity, and maintains an isotonic environment, thereby achieving efficient inactivation and stable preservation.
Core Advantages:
Dimension | Traditional guanidinium salt system | Lidin non-guanidine salt system |
Nucleic acid extraction compatibility | ⭐⭐ | ⭐⭐⭐⭐⭐ |
RNA stability | ⭐⭐ | ⭐⭐⭐⭐⭐ |
Resistance to organic interference | ⭐⭐ | ⭐⭐⭐⭐⭐ |
Suitable for long-term storage and transportation | ⭐⭐ | ⭐⭐⭐⭐⭐ |
Application scenarios: Third-party medical laboratories, disease control centers, cross-border and interregional sample transportation, and automated nucleic acid extraction platforms.
Endless wisdom, a river of innovation through patent aggregation.
As a pioneer of innovation in the in vitro diagnostics industry, Leading Medical remains committed to its original mission of technological breakthroughs, relentlessly advancing on the path of precision medicine. To date, the company has filed a total of 86 patent applications, including 52 invention patents, with 38 of these invention patents having been successfully granted and put into practical use. A single patent encapsulates the R&D team’s tireless, round-the-clock efforts—day and night—of dedicated research and relentless problem-solving, bearing witness to Liding’s unwavering commitment to empowering public health through cutting-edge innovation.
Innovation knows no bounds, and the drive to excel never stops.
Going forward, Leading Medical will continue to ramp up its investment in R&D, focus on overcoming key technological barriers in the in vitro diagnostics field, consistently deliver high‑quality, proprietary innovations, and strengthen its core competitive advantages. By sustaining a steady stream of innovative momentum, the company will help drive the domestic IVD industry toward high‑quality growth.
2022-07-26
xy13584019024